A cost-effectiveness analysis (CEA) is a type of economic evaluation that compares the relative costs and health outcomes of different medical interventions or treatments. The goal of a CEA is to determine the most cost-effective option, or the option that provides the most health benefit for the resources invested.
To conduct a CEA, the costs and health outcomes associated with each intervention or treatment are estimated, and then compared. The health outcomes are typically measured in a unit such as quality-adjusted life years (QALYs), which take into account both the quantity of life gained and the quality of life experienced during that time.
The ratio of the costs to the health outcomes is known as the incremental cost-effectiveness ratio (ICER), which expresses the additional cost per unit of health benefit gained from one intervention compared to another. A lower ICER is generally considered more cost-effective.
CEA can be used in a variety of settings, including in the assessment of new drugs and medical devices, and in the allocation of healthcare resources. It can also be used to compare different treatment options for a specific condition or disease, and to identify the most cost-effective option.
It should be noted that CEA is not without criticisms, which include concerns about valuing different lives differently and ethical issues that arise from the use of CEA in resource allocation. Additionally, CEA results are often sensitive to the assumptions made, such as the time horizon and the perspective (e.g. healthcare system, society) used.
In conclusion, cost-effectiveness analysis (CEA) is a type of economic evaluation that compares the relative costs and health outcomes of different medical interventions or treatments. It aims to determine the most cost-effective option, and is typically measured by the incremental cost-effectiveness ratio (ICER). CEA can be used in a variety of settings and can inform healthcare decision-making. However, it is important to consider the potential limitations and ethical issues when interpreting and using the results.
For more information, please see our other posts on HTA related topics.
For questions or remarks, contact us at: [email protected]